Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pelabresib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 known ✓ | O60885 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pelabresib SCHEMBL29382955 | 1.00 | BRD4 (1.00) | BRD4 | |
| Pelabresib SCHEMBL23289020 | 1.00 | BRD4 (1.00) | BRD4 | |
| Pelabresib SCHEMBL17354054 | 0.99 | BRD4 (0.98) | BRD4 | |
| SCHEMBL17854821 | 0.91 | BRD4 (1.00) | BRD4 | |
| SCHEMBL15926492 | 0.91 | BRD4 (0.83) | BRD4 | |
| SCHEMBL30411255 | 0.91 | BRD4 (0.83) | BRD4 | |
| SCHEMBL9282455 | 0.91 | BRD4 (0.83) | BRD4 | |
| SCHEMBL15925864 | 0.91 | BRD4 (0.83) | BRD4 | |
| SCHEMBL15925868 | 0.91 | BRD4 (0.83) | BRD4 | |
| SCHEMBL15926513 | 0.90 | BRD4 (1.00) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1683 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102321-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | MARO BIO INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| EP-3664807-B1 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-19 | — | — | EP | claimed |
| EP-4637778-A1 | METHODS FOR TREATING LOWER RISK MYELODYSPLASTIC SYNDROME | Constellation Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250281502-A1 | NEW DRUG APPLICATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-09-11 | — | — | US | claimed |
| EP-4611753-A1 | PIM1 INHIBITOR FOR TREATING MYELOPROLIFERATIVE NEOPLASMS | Sumitomo Pharma America, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | claimed |
| WO-2025151706-A1 | EPIGENETIC REAGENTS AND UTILIZATION OF CAR NK CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2020256739-A1 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2020-12-24 | — | — | WO | claimed |
| WO-2020257644-A1 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2020-12-24 | — | — | WO | claimed |
| WO-2020112939-A1 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2020-06-04 | — | — | WO | claimed |
| WO-2020112086-A1 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2020-06-04 | — | — | WO | claimed |
| EP-3157928-B1 | CRYSTALLINE FORMS OF 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-02-13 | — | — | EP | claimed |
| US-9969747-B2 | Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | claimed |
| US-20170137434-A1 | CRYSTALLINE FORMS OF 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE | CONSTELLATION PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | claimed |
| EP-3157928-A1 | CRYSTALLINE FORMS OF 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE | Constellation Pharmaceuticals, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| WO-2015195863-A1 | HYDRATED 2-((4S)-6-(4-CHLOROPHENYL)-1 -METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015195862-A1 | CRYSTALLINE FORMS OF 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4S5-E]AZEPIN-4-YL)ACETAMIDE | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | BRD4 13/4885 |
| US-20170137434-A1 | CRYSTALLINE FORMS OF 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE | BRD4, BRPF3, BRDT | BRD4 1/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | BRD4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.